Reduction of invasive biopsies by proteome analysis!

Jan. 2023  

In an international prospective study including 970 patients, detection and assessment of prostate cancer (PCa) by CE-MS has been demonstrated to be of significant value in reducing invasive biopsies. Integration of CE-MS derived biomarkers via machine learning improves our ability to detect PCa using urine samples without the need for prior digital rectal examination.